Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Science-Based Medicine
2 Monotherapy is no longer available in the USA since Jan 2023, and lixisenatide-glargine (iGlarLixi) has been approved for type 2 diabetes
Indeed, in 23 patients out of a total of 25, 5-MTHF in CSF was low despite normal serum folate treatment with folinic acid for a year restored folate levels and led to clinical improvements
Through such comprehensive genetic analyses, PRSs holds the potential to advance our ability to tailor preventive and therapeutic strategies based on individual genetic risk profiles, paving the way for precision medicine for IR-psychiatric multimorbidity
In this, we reinvestigate already FDA-approved drugs for attaining new therapeutic benefits, as these are already in supply chains and have proven clinical safety profiles with shorter timelines
US$ 20.96
US$ 27.23
US$ 20.39
US$ 27.74
